The pharma area is staying hot and the people considering reducing the costs of medical realize that it can be done with the advancement of drugs that will both sustain life and a true quality of life as opposed to continuing costs where the patient has little incentive to live.
The continued expansion by SGEN into multiple areas of cancer treatment that is patient specific is the progression into becoming a major pharma player. Issue here is whether they will remain independent or be taken over by a pharma company that understands the potential.